Intervention

AZD4635

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting0

Common conditions8

Lead sponsors shown2

Clinical trials

4 shown

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.NCT04495179 · 2020-08-04

An Open-label, Phase II Study of AZD4635 in Patients With Prostate CancerNCT04089553 · 2019-08-29

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination StudyNCT03381274 · 2018-05-08

ACTIVE_NOT_RECRUITING

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid MalignanciesNCT02740985 · 2016-06-17

Common conditions

Advanced Solid Malignancies1 Carcinoma, Non-Small-Cell Lung1 Colorectal Carcinoma (CRC)1 Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)1 Metastatic Castration-Resistant Prostate Cancer (mCRPC)1 Non-Small Cell Lung Cancer (NSCLC)1 Progressive Metastatic Castrate-Resistant Prostate Cancer1 Prostate Cancer1

Leading sponsors

AstraZeneca3 MedImmune LLC1

Trial status mix

COMPLETED3

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE23

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.